This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Keytruda is a cancer immunotherapy, which stimulates the immune system to attack tumor cells and is the best-selling medicine in the world. patent expires in 2028. The subcutaneous injection could be given in a doctor’s office every six weeks, instead of requiring a 30-minute IV drip at the same interval.
Lupin, a global pharmaceuticalcompany, has announced its tentative approval from the United States Food and Drug Administration (U.S. This medication targets the virus, aiming to lower viral load and improve immune function in affected individuals. according to IQVIA data for the 12 months ending September 2024.
The PLI Scheme for Pharmaceuticals aims to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector.
This is progressing through a phase 3 trial and includes comparator arms with standard-of-care treatments like daratumumab, bortezomib (Velcade; Millennium/Takeda and Janssen PharmaceuticalCompanies), and lenalidomide. 2 We’re still trying to figure out where these new treatments best fit.
In 2022, based upon a complaint filed by a pharmaceuticalcompany, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. So, the pharmaceuticalcompanies then pushed to get their 505(b)(2) drugs declared sole source,” Soefje said. “If This went into effect in January 2022.”
Backed by more than 40 real-world studies involving 250,000 immunized infants, Beyfortus has consistently proven itself as an effective RSV immunization,” said Thomas Triomphe, Sanofi’se xecutive vice president of vaccines.“To “Our third year of providing RSV protection marks a transformative era in infant health. May 25, 2025.
According to a recent analysis on Pharma Marketing Network , portfolio managers are advising caution in the Asia-Pacific pharmaceutical sector until regulatory clarity and new pricing structures stabilize. Though these companies operate on longer timelines and more complex supply chains, they arent immune. Is the U.S.
Additionally, we are expanding our regulatory approvals to enter international markets and are engaging with global health organisations to integrate needle-free technology into immunization programs, making injections safer and more accessible worldwide. Have needle-free injection systems made inroads into the existing injection market?
The farsighted pharmaceuticalcompanies are waking up to the importance of AI agents. As regulations become stricter and HCPs become immune to promotional noise, this solution ensures compliance while helping you craft messages that hit home every time (and do so faster). What the Future Holds for Us?
The CDC’s Advisory Committee on Immunization Practices voted 5-1 in June to recommend only single-dose flu vaccines — which are all free of the preservative — be administered in the U.S. The HHS secretary has said the restructuring will reduce conflicts of interest with pharmaceuticalcompanies. The post RFK Jr.
The company also paused a study meant to confirm Elevidys’ benefits in these patients, and convert the therapy’s current “accelerated” approval in these patients to a traditional one. Sarepta is working on a new regimen of immune-suppressing drugs to manage the safety risks, and plans to soon share its findings with the FDA.
billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drug developer since April 2023. Track the deals that are happening here. Sanofi’s $9.1 Track the deals that are happening here. Sanofi’s $9.1
s Advisory Committee on Immunization Practices. s independent scientific body on immunization. This is despite promising early data on the effectiveness of the company’s bird flu vaccine, and an urgent need for more pandemic response tools. The firing of the A.C.I.P. The committee has served for decades as the C.D.C.’s
CD is said to be a chronic inflammatory condition of the gastrointestinal tract with a complex aetiology involving immune system abnormalities, which may be influenced by genetic, dietary, or environmental factors. Johnson & Johnson’s Janssen PharmaceuticalCompanies hold exclusive global marketing rights to the therapy.
The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.
RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. Historically, federal funding has been used to develop vaccines, as infectious disease markets are often not as lucrative as other indications.
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The drug candidate is an engineered B-cell modulator.
It is claimed to have outperformed an antiviral drug in lowering various proinflammatory mediators linked to hyperinflammation and dysfunction of the immune system after viral infection. Qifenda is a broad-spectrum antiviral drug in the commercial stage. Developed by FujiFilm Toyama Chemical, Favipiravir is currently owned by Cellvera.
Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).
The oncology segment has been recognised as one of the most productive areas for pharmaceuticalcompanies to focus their R&D investment. Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology. A broad front.
In a document outlining the charges against Shafat Quadri, of North Potomac, Maryland the US Department of Justice (DoJ) referred only to “one of the largest pharmaceuticalcompanies in the world” based in New Jersey.
The pharmaceuticalcompany announced that it plans to submit to global health authorities in 2024. appeared first on European Pharmaceutical Review. The REMIX data for Novartis’ novel BTK inhibitor will be presented at an upcoming medical meeting. There were 470 participants in the REMIX-1 study.
Janssen PharmaceuticalCompanies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).
The investigational combination mRNA vaccine generated statistically significant higher immune responses in relation to the licensed comparator vaccines used in the randomised, observer-blind, active control study among 8,000 adults aged 50 years and older. Fluzone high-dose and Fluarix for influenza, and Spikevax for Covid-19.
IL-13 has a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms. The monoclonal antibody biologic treatment has been developed to bind to and inhibit the interleukin (IL)-13 cytokine. It inhibits interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. AC Immune and F. Hoffmann-La Roche are the other key patent filers in neuro-degenerative receptor binding drug compositions.
Most drugs available for the treatment of UC weaken patients’ immune systems, which puts them at higher risk of infection. Key opinion leaders (KOLs) interviewed by GlobalData have suggested that this group of patients would benefit from a greater number of treatment options that cause less systemic immune-related side effects.
Australian pharmaceuticalcompany Incannex has appointed Quest Pharmaceutical Services (QPS) to advance CannQuit-N (Nicotine), CannQuit-O (Opioid) and Renecann Products in the USA and the European Union (EU). French company Eurofins Scientific is currently developing and manufacturing both products.
A fully human monoclonal antibody, Libtayo acts on the immune checkpoint receptor PD-1 on T cells. The company’s footprint spans 16 markets and employs over 12,000 individuals. It is said to be the first-line monotherapy approved for advanced non-small cell lung cancer (NSCLC).
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.
Mukherjee explained that the human immune system becomes weaker as people age, which leads to a greater susceptibility to catching infectious diseases and also experiencing more acute cases when infected.
Some pharmaceuticalcompanies, including Chiesi, established emergency committees to build business continuity plans and contingencies to protect drug supply and worker safety. Despite COVID-19, we expanded the new business unit to 275 employees in more than 20 countries in just 18 months.
The truth is that most supplement companies do not undergo the same scrutiny and testing that pharmaceutical products do, because many of the tests which are required of pharmaceuticalcompanies are voluntary for supplement companies. We have 290 expiring in April 2025.)
Datroway is currently being evaluated in five Phase III clinical trials as a first-line therapy in combination with immune checkpoint inhibitors (ICIs), bispecific antibodies, and epidermal growth factor receptor inhibitors. AbbVie, AstraZeneca, and Daiichi Sankyo.
At the same time, lots of people with experience at multinational pharmaceuticalcompanies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceuticalcompanies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%
Cue Biopharma overview Cue Biopharma operates as pharmaceuticalcompany. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content